MiRNA-183-5p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting the PDCD4

被引:91
作者
Cheng, Yan [1 ]
Xiang, Guixian [1 ]
Meng, Yanbo [1 ]
Dong, Runzhi [2 ]
机构
[1] Xingtai Med Coll, Dept Pharmacol, 618 Gangtie Rd, Xingtai 054000, Hebei Province, Peoples R China
[2] Xingtai Peoples Hosp, Dept Tradit Chinese Med, Xingtai 054000, Peoples R China
关键词
miR-183-5p; PDCD4; Cell proliferation; Cell cycle; Apoptosis; Breast cancer; TUMOR-SUPPRESSOR PDCD4; HEPATOCELLULAR-CARCINOMA CELLS; DEATH; 4; DOWN-REGULATION; GASTRIC-CANCER; INVASION; EXPRESSION; MIGRATION; MICRORNA; CONSEQUENCES;
D O I
10.1016/j.repbio.2016.07.002
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
MicroRNAS are often aberrantly expressed in breast cancer and postulated to play a causal role in the onset and maintenance of breast cancer by binding to its target mRNA. Here, we evaluated the effects of miRNA-183-5p on cell proliferation and apoptosis which attempted to elucidate the potential role of miR-183-5p/PDCD4 axis in human breast cancer. We found that the miR-183-5p expression level was extremely promoted in breast cancer in comparison with the adjacent normal tissues. Overexpression of miR-183-5p significantly enhanced the cell proliferation and inhibited cell apoptosis in MCF-7 and MDA-MB-231 cells. Moreover, PDCD4 was predicted as a putative target of miR-183-5p by bioinformatic approaches, and miR-183-5p negatively regulated the expression of PDCD4. Furthermore, knockdown of PDCD4 suppressed expression of p21 and p27, which was consistent with the result of the attachment of miR-183-5p. These data collectively demonstrate that miR-183-5p exerts oncomiRs effects in breast cancer, and may have broad impacts on the field of using antimiRs as anti-cancer drugs for breast cancer. (C) 2016 Published by Elsevier Sp. z o.o. on behalf of Society for Biology of Reproduction & the Institute of Animal Reproduction and Food Research of Polish Academy of Sciences in Olsztyn.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 47 条
[1]   Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives [J].
Ades, Felipe ;
Zardavas, Dimitrios ;
Bozovic-Spasojevic, Ivana ;
Pugliano, Lina ;
Fumagalli, Debora ;
de Azambuja, Evandro ;
Viale, Giuseppe ;
Sotiriou, Christos ;
Piccart, Martine .
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (25) :2794-+
[2]  
[Anonymous], TUMOUR BIOL
[3]  
Barh D, 2010, CURR ONCOL, V17, P70
[4]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[5]   Causes and consequences of microRNA dysregulation in cancer [J].
Croce, Carlo M. .
NATURE REVIEWS GENETICS, 2009, 10 (10) :704-714
[6]   The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups [J].
Curtis, Christina ;
Shah, Sohrab P. ;
Chin, Suet-Feung ;
Turashvili, Gulisa ;
Rueda, Oscar M. ;
Dunning, Mark J. ;
Speed, Doug ;
Lynch, Andy G. ;
Samarajiwa, Shamith ;
Yuan, Yinyin ;
Graef, Stefan ;
Ha, Gavin ;
Haffari, Gholamreza ;
Bashashati, Ali ;
Russell, Roslin ;
McKinney, Steven ;
Langerod, Anita ;
Green, Andrew ;
Provenzano, Elena ;
Wishart, Gordon ;
Pinder, Sarah ;
Watson, Peter ;
Markowetz, Florian ;
Murphy, Leigh ;
Ellis, Ian ;
Purushotham, Arnie ;
Borresen-Dale, Anne-Lise ;
Brenton, James D. ;
Tavare, Simon ;
Caldas, Carlos ;
Aparicio, Samuel .
NATURE, 2012, 486 (7403) :346-352
[7]   Programmed cell death 4 protein in esophageal cancer [J].
Fassan, Matteo ;
Cagol, Matteo ;
Pennelli, Gianmaria ;
Rizzetto, Christian ;
Giacomelli, Luciano ;
Battaglia, Giorgio ;
Zaninotto, Giovanni ;
Ancona, Ermanno ;
Ruol, Alberto ;
Rugge, Massimo .
ONCOLOGY REPORTS, 2010, 24 (01) :135-139
[8]   Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells [J].
Frankel, Lisa B. ;
Christoffersen, Nanna R. ;
Jacobsen, Anders ;
Lindow, Morten ;
Krogh, Anders ;
Lund, Anders H. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (02) :1026-1033
[9]   Lost in transcription: p21 repression, mechanisms, and consequences [J].
Gartel, AL ;
Radhakrishnan, SK .
CANCER RESEARCH, 2005, 65 (10) :3980-3985
[10]  
Gu W, 2014, INT J CLIN EXP MED, V7, P2519